Abstract #3431

Anti-FGFR1/KLB treatment reduces hepatic fat fraction in a murine model of NAFLD

Maj Hedehus¹, Mark Z. Chen², Jose Zavala-Solorio², Lance Kates², Oded Foreman³, Junichiro Sonoda², and Richard A. D. Carano¹

¹Biomedical Imaging, Genentech, Inc., South San Francisco, CA, United States, ²Molecular Biology, Genentech, Inc., South San Francisco, CA, United States, ³Research Pathology, Genentech, Inc., South San Francisco, CA, United States

Anti-FGFR1/KLB is a novel experimental therapy to treat metabolic disorders and reverse lipid accumulation in the liver. MRI estimates of proton density fat fraction demonstrated a dose-dependent anti-FGFR1/KLB treatment effect in a murine model of NAFLD.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.